Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jul;16(7):1174.
doi: 10.1016/j.cgh.2018.03.011. Epub 2018 Mar 15.

Predictors of Response to Terlipressin in Hepatorenal Syndrome

Ayse L Mindikoglu  1 , Stephen C Pappas  2
Affiliations
Comment

Predictors of Response to Terlipressin in Hepatorenal Syndrome

Ayse L Mindikoglu et al. Clin Gastroenterol Hepatol. 2018 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018;16:162–177. e1. - PMC - PubMed
    1. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315–21. - PMC - PubMed
    1. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51:219–26. - PubMed
    1. Piano S, Schmidt HH, Ariza X, et al. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 - PubMed
    1. Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45:1390–1402. - PMC - PubMed